Clinical Trial Update: An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS) [Phase 3]

View source ↗

Summary

Extension study to continue azacitidine in patients with myelodysplastic syndromes after completion of the main AZA PH GL 2003 CL 001 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndromes | Phase 3 | Status: COMPLETED | Results posted: 2010-09-21